Premium
Exons 16 and 17 of the amyloid precursor protein gene in familial inclusion body myopathy
Author(s) -
Sivakumar K.,
Cervenáková L.,
Dalakas M. C.,
LeonMonzon M.,
Isaacson S. H.,
Nagle J. W.,
Vasconcelos O.,
Goldfarb L. G.
Publication year - 1995
Publication title -
annals of neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.764
H-Index - 296
eISSN - 1531-8249
pISSN - 0364-5134
DOI - 10.1002/ana.410380222
Subject(s) - myopathy , exon , inclusion bodies , amyloidosis , amyloid (mycology) , mutation , amyloid precursor protein , biology , pathology , gene mutation , allele , gene , genetics , alzheimer's disease , medicine , endocrinology , disease , escherichia coli
Accumulation of β‐amyloid protein (Aβ) occurs in some muscle fibers of patients with inclusion body myopathy and resembles the type of amyloid deposits seen in the affected tissues of patients with Alzheimer's disease and cerebrovascular amyloidosis. Because mutations in exons 16 and 17 of the β‐amyloid precursor protein (βAPP) gene on chromosome 21 have been identified in patients with early‐onset familial Alzheimer's disease and Dutch‐type cerebrovascular amyloidosis, we searched for mutations of the same region in patients with familial inclusion body myopathy. Sequencing of both alleles in 8 patients from four unrelated families did not reveal any mutations in these exons. The amyloid deposition in familial forms of inclusion body myopathy may be either due to errors in other gene loci, or it is secondary reflecting altered βAPP metabolism or myocyte degeneration and cell membrane degradation.